The North America Age Related Macular Degeneration (AMD) Market would witness market growth of 4.9% CAGR during the forecast period (2023-2030).
The most common cause of blindness in senior patients in developed nations is age-related macular degeneration (AMD). It is an eye condition that affects older people's eyes and leads to a progressive loss of the central vision needed for tasks like reading, driving, recognizing people, and examining color. As AMD worsens, many patients lose their ability to read, write, or distinguish between colors and details, which lowers their quality of life. Although the precise functional cause of AMD is not yet fully known, recent advancements in genetic technology have allowed for the identification of several variants that have been found to have distinctive relationships with the disease.
The center of vision becomes blurry as a result. A blood vessel growth abnormality could cause loss of eyesight. On rare occasions, it may be possible to identify abnormal new blood vessels developing from the choroid into the macula. The choroid (sclera), made up of a layer of blood vessels, is located between the retina and the outside, a solid coat of the eye. These abnormal blood vessels may leak blood or fluid, impairing the retina's ability to function.
As the first biosimilar to Lucentis (ranibizumab injection), the U.S. Food and Drug Administration approved Byooviz (ranibizumab-nuna) for the treatment of several eye diseases and conditions, including neovascular (wet) age-related macular degeneration (AMD), a major cause of vision loss and blindness among Americans aged 65 and beyond. Additionally, byooviz is authorized for the treatment of myopic choroidal neovascularization, a risky eye condition brought about by myopia (nearsightedness), as well as macular edema (fluid buildup) following retinal vein occlusion (blockage of veins in the retina). According to the National Library of Administration, 6.8 million people in Canada, or 18% of the total population, were over 65 in 2020. Older people will make up 23% of the population by 2030 when Canada's life expectancy is anticipated to rise from 84.2 to 86.2 years. The market in this region is expected to develop due to the medications' approval and the region's aging population.
The US market dominated the North America Age Related Macular Degeneration (AMD) Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $4,478.1 million by 2030. The Canada market is experiencing a CAGR of 7.2% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 6.3% during (2023 - 2030).
Based on Drug Type, the market is segmented into Aflibercept, Ranibizumab and Others. Based on Disease Type, the market is segmented into Wet and Dry. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Age Related Macular Degeneration (AMD) Market is Projected to reach USD 13.9 Billion by 2030, at a CAGR of 5.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biogen, Inc., Bayer AG, Apellis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Ionis Pharmaceuticals, Inc., Novartis AG, Sanofi S.A., Coherus Biosciences, Inc. and Bausch Health Companies, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Drug Type
- Aflibercept
- Ranibizumab
- Others
By Disease Type
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Biogen, Inc.
- Bayer AG
- Apellis Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals, Inc.
- F.Hoffmann-La Roche Ltd.
- Ionis Pharmaceuticals, Inc.
- Novartis AG
- Sanofi S.A.
- Coherus Biosciences, Inc.
- Bausch Health Companies, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Age Related Macular Degeneration (AMD) Market, by Drug Type
1.4.2 North America Age Related Macular Degeneration (AMD) Market, by Disease Type
1.4.3 North America Age Related Macular Degeneration (AMD) Market, by Distribution Channel
1.4.4 North America Age Related Macular Degeneration (AMD) Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter Five Forces Analysis
Chapter 4. Strategies deployed in Age Related Macular Degeneration (AMD) Market
Chapter 5. North America Age Related Macular Degeneration (AMD) Market by Drug Type
5.1 North America Aflibercept Market by Country
5.2 North America Ranibizumab Market by Country
5.3 North America Others Market by Country
Chapter 6. North America Age Related Macular Degeneration (AMD) Market by Disease Type
6.1 North America Wet Market by Country
6.2 North America Dry Market by Country
Chapter 7. North America Age Related Macular Degeneration (AMD) Market by Distribution Channel
7.1 North America Hospital Pharmacy Market by Country
7.2 North America Retail Pharmacy Market by Country
7.3 North America Online Pharmacy Market by Country
Chapter 8. North America Age Related Macular Degeneration (AMD) Market by Country
8.1 US Age Related Macular Degeneration (AMD) Market
8.1.1 US Age Related Macular Degeneration (AMD) Market by Drug Type
8.1.2 US Age Related Macular Degeneration (AMD) Market by Disease Type
8.1.3 US Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.2 Canada Age Related Macular Degeneration (AMD) Market
8.2.1 Canada Age Related Macular Degeneration (AMD) Market by Drug Type
8.2.2 Canada Age Related Macular Degeneration (AMD) Market by Disease Type
8.2.3 Canada Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.3 Mexico Age Related Macular Degeneration (AMD) Market
8.3.1 Mexico Age Related Macular Degeneration (AMD) Market by Drug Type
8.3.2 Mexico Age Related Macular Degeneration (AMD) Market by Disease Type
8.3.3 Mexico Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.4 Rest of North America Age Related Macular Degeneration (AMD) Market
8.4.1 Rest of North America Age Related Macular Degeneration (AMD) Market by Drug Type
8.4.2 Rest of North America Age Related Macular Degeneration (AMD) Market by Disease Type
8.4.3 Rest of North America Age Related Macular Degeneration (AMD) Market by Distribution Channel
Chapter 9. Company Profiles
9.1 Biogen, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.6 SWOT Analysis
9.2 Bayer AG
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 SWOT Analysis
9.3 Apellis Pharmaceuticals, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental Analysis
9.3.4 Research & Development Expenses
9.3.5 Recent strategies and developments:
9.3.5.1 Approvals & Trails:
9.3.6 SWOT Analysis
9.4 Regeneron Pharmaceuticals, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Research & Development Expense
9.4.4 SWOT Analysis
9.5 F. Hoffmann-La Roche Ltd.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 SWOT Analysis
9.6 Ionis Pharmaceuticals, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Research & Development Expenses
9.6.4 SWOT Analysis
9.7 Novartis AG
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Approvals & Trails:
9.7.5.2 Acquisition and Mergers:
9.7.6 SWOT Analysis
9.8 Sanofi S.A.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 SWOT Analysis
9.9 Coherus Biosciences, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 Recent strategies and developments:
9.9.4.1 Approvals & Trials:
9.9.5 SWOT Analysis
9.1 Bausch Health Companies, Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expense
9.10.5 Recent strategies and developments:
9.10.5.1 Product Launches and Product Expansions:
9.10.6 SWOT Analysis
TABLE 1 North America Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 2 North America Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 3 North America Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 4 North America Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 5 North America Aflibercept Market by Country, 2019 - 2022, USD Million
TABLE 6 North America Aflibercept Market by Country, 2023 - 2030, USD Million
TABLE 7 North America Ranibizumab Market by Country, 2019 - 2022, USD Million
TABLE 8 North America Ranibizumab Market by Country, 2023 - 2030, USD Million
TABLE 9 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 10 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 11 North America Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 12 North America Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 13 North America Wet Market by Country, 2019 - 2022, USD Million
TABLE 14 North America Wet Market by Country, 2023 - 2030, USD Million
TABLE 15 North America Dry Market by Country, 2019 - 2022, USD Million
TABLE 16 North America Dry Market by Country, 2023 - 2030, USD Million
TABLE 17 North America Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 18 North America Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 19 North America Hospital Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 20 North America Hospital Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 21 North America Retail Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 22 North America Retail Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 23 North America Online Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 24 North America Online Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 25 North America Age Related Macular Degeneration (AMD) Market by Country, 2019 - 2022, USD Million
TABLE 26 North America Age Related Macular Degeneration (AMD) Market by Country, 2023 - 2030, USD Million
TABLE 27 US Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 28 US Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 29 US Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 30 US Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 31 US Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 32 US Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 33 US Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 34 US Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 35 Canada Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 36 Canada Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 37 Canada Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 38 Canada Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 39 Canada Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 40 Canada Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 41 Canada Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 42 Canada Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 43 Mexico Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 44 Mexico Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 45 Mexico Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 46 Mexico Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 47 Mexico Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 48 Mexico Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 49 Mexico Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 50 Mexico Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 51 Rest of North America Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 52 Rest of North America Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 53 Rest of North America Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 54 Rest of North America Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 55 Rest of North America Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 56 Rest of North America Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 57 Rest of North America Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 58 Rest of North America Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 59 Key Information – Biogen, Inc.
TABLE 60 Key Information – Bayer AG
TABLE 61 Key Information – Apellis Pharmaceuticals, Inc.
TABLE 62 Key Information – Regeneron Pharmaceuticals, Inc.
TABLE 63 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 64 Key information – Ionis Pharmaceuticals, Inc.
TABLE 65 Key Information – Novartis AG
TABLE 66 Key Information – Sanofi S.A.
TABLE 67 Key Information – Coherus Biosciences, Inc.
TABLE 68 key information – Bausch Health Companies, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 North America Age Related Macular Degeneration (AMD) Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Age Related Macular Degeneration (AMD)Market
FIG 4 Porter’s Five Forces Analysis – Age Related Macular Degeneration (AMD) Market
FIG 5 North America Age Related Macular Degeneration (AMD) Market share by Drug Type, 2022
FIG 6 North America Age Related Macular Degeneration (AMD) Market share by Drug Type, 2030
FIG 7 North America Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2030, USD Million
FIG 8 North America Age Related Macular Degeneration (AMD) Market share by Disease Type, 2022
FIG 9 North America Age Related Macular Degeneration (AMD) Market share by Disease Type, 2030
FIG 10 North America Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2030, USD Million
FIG 11 North America Age Related Macular Degeneration (AMD) Market share by Distribution Channel, 2022
FIG 12 North America Age Related Macular Degeneration (AMD) Market share by Distribution Channel, 2030
FIG 13 North America Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2030, USD Million
FIG 14 North America Age Related Macular Degeneration (AMD) Market share by Country, 2022
FIG 15 North America Age Related Macular Degeneration (AMD) Market share by Country, 2030
FIG 16 North America Age Related Macular Degeneration (AMD) Market by Country, 2019 - 2030, USD Million
FIG 17 Swot Analysis: Biogen, Inc.
FIG 18 Swot Analysis: Bayer AG
FIG 19 Swot Analysis: Apellis Pharmaceuticals, Inc.
FIG 20 Swot Analysis: Regeneron Pharmaceuticals, Inc.
FIG 21 Swot Analysis: F. Hoffmann-La Roche Ltd.
FIG 22 Swot Analysis: Ionis Pharmaceuticals, Inc.
FIG 23 SWOT Analysis: Novartis AG
FIG 24 Swot Analysis: Sanofi S.A.
FIG 25 Swot Analysis: Coherus Biosciences, Inc.
FIG 26 Swot Analysis: Bausch Health Companies, Inc.